Portrazza Uniunea Europeană - slovacă - EMA (European Medicines Agency)

portrazza

eli lilly nederland b.v. - necitumumab - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - portrazza v kombinácii s chemoterapiou gemcitabínu a cisplatiny je indikovaný na liečbu dospelých pacientov s lokálne pokročilým alebo metastázujúcim receptor epidermálneho rastového (faktora egfr) vyjadrenie dlaždicové non-malá bunka rakovina pľúca ktorí predtým nedostávali chemoterapiu pre túto podmienku.

Tagrisso Uniunea Europeană - slovacă - EMA (European Medicines Agency)

tagrisso

astrazeneca ab - osimertinib mesilate - karcinóm, pľúc bez malých buniek - iné antineoplastické činidlá, protein kinase inhibítory - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Pregabalin Zentiva Uniunea Europeană - slovacă - EMA (European Medicines Agency)

pregabalin zentiva

zentiva, k.s. - pregabalín - anxiety disorders; epilepsy - antiepileptiká, - neuropathic pain , pregabalin zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , epilepsy , pregabalin zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , generalised anxiety disorder , pregabalin zentiva is indicated for the treatment of generalised anxiety disorder (gad) in adults.

Roteas Uniunea Europeană - slovacă - EMA (European Medicines Agency)

roteas

berlin-chemie ag - edoxaban tosilate - stroke; venous thromboembolism - antitrombotické činidlá - prevencia mozgovej príhody a systémovej embólie u dospelých pacientov s nevalvulárnou fibriláciou predsiení (nvaf) s jedným alebo viacerými rizikovými faktormi, ako je kongestívne srdcové zlyhanie, hypertenzia, vek ≥ 75 rokov, diabetes mellitus, predchádzajúca mozgová príhoda alebo prechodný ischemický záchvat ( tia). liečba hlbokej žilovej trombózy (dvt) a pľúcna embólia (pe), a prevencia opakujúcich sa dvt a pe u dospelých.

Sialanar Uniunea Europeană - slovacă - EMA (European Medicines Agency)

sialanar

proveca pharma limited - glycopyrronium bromid - sialorrhea - liečivá na funkčné gastrointestinálne poruchy - symptomatická liečba závažnej sialorrhoe (chronické ochorenie srdca) u detí a dospievajúcich vo veku 3 rokov a starších s chronickými neurologickými poruchami.

Vectibix Uniunea Europeană - slovacă - EMA (European Medicines Agency)

vectibix

amgen europe b.v. - panitumumab - kolorektálne novotvary - antineoplastické činidlá - vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc): , in first-line in combination with folfox or folfiri. v druhej línii v kombinácii s folfiri pre pacientov, ktorí dostali v prvej línii fluoropyrimidine-založené chemoterapie (s výnimkou irinotecan). ako monotherapy po poruche fluoropyrimidine-, oxaliplatin-a irinotecan-obsahujúce chemoterapia režimy.

Vidaza Uniunea Europeană - slovacă - EMA (European Medicines Agency)

vidaza

bristol-myers squibb pharma eeig - azacitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastické činidlá - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Zaltrap Uniunea Europeană - slovacă - EMA (European Medicines Agency)

zaltrap

sanofi winthrop industrie - aflibercept - kolorektálne novotvary - antineoplastické činidlá - liečba metastatického kolorektálneho karcinómu (mcrc).

DICYNONE 250 Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

dicynone 250

omedicamed, unipessoal lda, portugalsko - etamsylát - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

DICYNONE 250 Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

dicynone 250

om pharma s.a., portugalsko - etamsylát - 16 - anticoagulantia (fibrinolytica, antifibrinol.)